This article describes an analytical method for the detection of cannabinoids in oral fluid. The method utilizes an Agilent 5975 GC/MS instrument and allows for the simultaneous determination of Δ9-tetrahydrocannabinolic acid A (THCA-A), tetrahydrocannabinol (THC), cannabinol (CBN), and cannabidiol (CBD) in oral fluid samples. The method achieves the required sensitivity for the detection of THC, CBN, CBD, and THCA-A in oral fluid specimens taken from a habitual marijuana smoker.
This document presents an analytical procedure for the simultaneous determination of tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD), and the pyrolytic precursor 2-carboxy-THC in human oral fluid specimens. The method utilizes an Agilent 5975 GC/MS with an inert source to achieve the necessary sensitivity for these analytes, which are often present in lower concentrations in oral fluid compared to urine.
The study employs Immunalysis Corporation's QUANTISAL oral fluid collection device and details the sample preparation, including derivatization with BSTFA + 1% TMCS. The document provides specific instrument conditions, chromatographic parameters, and validation data, including limits of quantitation, linearity, and precision results for the detection of the target cannabinoids.
| Instrument | Agilent 6890 GC 5975 MSD; inert source |
|---|---|
| Limit of quantitation (THC) | 0.5 ng/mL |
The method uses a standard single quadrupole Agilent GC/MS 6890-5975 instrument.
The study employed Immunalysis Corporation's QUANTISAL oral fluid collection device.
The method achieves a limit of quantitation of 0.5 ng/mL for THC.
The quantitative ions monitored for unlabeled THC are 371.2, 386.2, and 303.1.